Efficacy of Anticholinergics for Chronic Prostatitis/Chronic Pelvic Pain Syndrome in Young and Middle-Aged Patients: A Single-Blinded, Prospective, Multi-Center Study.
- Author:
Doo Sang KIM
1
;
Yoon Soo KYUNG
;
Seung Hyo WOO
;
Young Seop CHANG
;
Hyung Jee KIM
Author Information
1. Department of Urology, Soonchunhyang University College of Medicine, Cheonan, Korea.
- Publication Type:Multicenter Study ; Randomized Controlled Trial ; Original Article
- Keywords:
Prostate;
Cholinergic antagonists;
Prostatitis
- MeSH:
Cholinergic Antagonists;
Ciprofloxacin;
Humans;
Incidence;
Lower Urinary Tract Symptoms;
Male;
National Institutes of Health (U.S.);
Pelvic Pain;
Prospective Studies;
Prostate;
Prostatitis;
Quality of Life;
Quinuclidines;
Solifenacin Succinate;
Tetrahydroisoquinolines
- From:International Neurourology Journal
2011;15(3):172-175
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) exhibits variable lower urinary tract symptoms (LUTS). The aim of this study was to evaluate the incidence of LUTS and the efficacy of an anticholinergic agent in young and middle-aged CP/CPPS patients. METHODS: Ninety-six men with CP/CPPS were randomly assigned in a single-blind fashion and received either ciprofloxacin (group 1, 49 patients) or ciprofloxacin and solifenacin (5 mg/day; group 2, 47 patients) for 8 weeks. The National Institutes of Health chronic prostatitis symptom index (NIH-CPSI), the International Prostate Symptom Score (IPSS), and the International Index of Erectile Function-5 (IIEF-5) were used to grade the patients' symptoms and the quality of life impact at the start of the study, and at 4 and 8 weeks from the initiation of the study. RESULTS: There was no significant difference between groups 1 and 2 with respect to age, duration of disease, or sub-domains of the IPSS, NIH-CPSI, or IIEF-5 at baseline. Of these patients, 67.4% had LUTS. Statistically significant differences were determined via the NIH-CPSI for total score and the pain and urinary domain scores. Statistically significant differences were determined via the IPSS for total score and the storage domain score. The total score of the IIEF-5 increased, but the change was not significant. There was no statistically significant difference in residual urine. CONCLUSIONS: Many CP/CPPS patients had LUTS. Solifenacin in CP/CPPS demonstrated improvements in the NIH-CPSI and the IPSS total score and storage score. Storage factors significantly improved via the NIH-CPSI and IPSS assessments in the solifenacin treatment group.
